Phanes starts dosing patients in mavrostobart chemo combo study

Phanes starts dosing patients in mavrostobart chemo combo study

By, Admin 29 May 2025

Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company, has announced that the first patient has been dosed in the clinical study of mavrostobart (PT199) in combination with chemotherapy.

About Mavrostobart (PT199)

Mavrostobart is an anti-CD73 monoclonal antibody with a differentiated mechanism of action, designed to counter the adenosine-mediated immunosuppressive tumour microenvironment (TME).

Key Advantages

  • Complete inhibition of enzyme activities from both soluble and membrane-bound CD73, surpassing many existing anti-CD73 antibodies that only offer incomplete inhibition
  • No “hook effect” even at higher concentrations, ensuring consistent inhibition
  • Addresses limitations of current CD73 inhibitors
  • Aims to enhance antitumor immune activation
  • Potentially offers a new treatment option for cancer patients

MORNINGSTAR Clinical Trial

The multi-center Phase I/II clinical trial of mavrostobart (ClinicalTrials.gov ID: NCT05431270), named the MORNINGSTAR study, is currently underway.

Study Objectives

  • Evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy
  • Test mavrostobart alone and in combination with a PD-1 inhibitor or chemotherapy

Global Reach

A Phase I clinical trial of mavrostobart is also being conducted in China (Clinical Trial Registry ID: CTR20242381).

About Phanes Therapeutics

Phanes Therapeutics, Inc. is a clinical-stage biotech company dedicated to innovative drug discovery and development in oncology.

Ongoing Clinical Programs

Phanes is currently conducting three Phase I/II clinical trials, including:

  • MORNINGSTAR study with mavrostobart (PT199) – a best-in-class monoclonal antibody (mAb)
  • TWINPEAK study with spevatamig (PT886)

SKYBRIDGE study with peluntamig (PT217)

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!